Document Detail


Sublingual immunotherapy reduces soluble HLA-G and HLA-A,-B,-C serum levels in patients with allergic rhinitis.
MedLine Citation:
PMID:  19100344     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Allergic rhinitis (AR) is characterized by Th2 polarized immune response. Soluble HLA (sHLA) molecules play an immunomodulatory activity. Specific immunotherapy is the only causal treatment for AR. So far no study investigated the effect of sublingual immunotherapy (SLIT) on sHLA molecules. The aim of the study was to evaluate sHLA-G and sHLA-A,-B,-C serum levels in AR patients with pollen allergy before and after a pre-seasonal course of SLIT. Forty AR patients with pollen allergy were enrolled and they assumed a pre-seasonal SLIT course for 3 months. Serum sHLA-G and sHLA-A,-B,-C and IFN-gamma and IL-4 levels were determined by ELISA method at baseline and 3 months after the end of the SLIT course. Symptoms severity was assessed by a Visual Analogue Scale. Both sHLA-G and sHLA-A,-B,-C levels significantly diminished (p<0.0001 for both) after SLIT. Moreover, there was a highly significant relationship between the serum levels of these two soluble molecules (r=0.84). Significant relationship between symptoms evaluated by VAS and change of sHLA molecules was also evidenced (r=0.60 and 0.63). Serum cytokines were not affected by SLIT. Therefore, this preliminary study provides the first evidence that both sHLA-G and sHLA-A,-B,-C levels are significantly reduced by SLIT in AR patients with pollen allergy. Therefore, the clinical implication of this study is that these soluble molecules might be interpreted as biomarker of response to SLIT.
Authors:
Giorgio Ciprandi; Paola Contini; Angela Pistorio; Giuseppe Murdaca; Francesco Puppo
Related Documents :
12671124 - Clinical, autoimmune, and hla characteristics of children diagnosed with type 1 diabete...
8679904 - Intrafamilial and case-control association analysis of d2s152 in insulin-dependent diab...
6334624 - Interaction of hla and immunoglobulin antigens in type 1 (insulin-dependent) diabetes.
7051714 - Increase of hla haplotype a9-bw16 in familial insulin-dependent diabetes mellitus in no...
1737544 - Benefits and risks with glyburide and glipizide in elderly niddm patients.
9236564 - Diabetic muscular infarction. preventing morbidity by avoiding excisional biopsy.
Publication Detail:
Type:  Controlled Clinical Trial; Journal Article     Date:  2008-12-17
Journal Detail:
Title:  International immunopharmacology     Volume:  9     ISSN:  1878-1705     ISO Abbreviation:  Int. Immunopharmacol.     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-01-26     Completed Date:  2009-04-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100965259     Medline TA:  Int Immunopharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  253-7     Citation Subset:  IM    
Affiliation:
DIMI, University of Genoa, Genoa, Italy. gio.cip@libero.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Sublingual
Adult
Allergens / administration & dosage*,  immunology
Desensitization, Immunologic / methods*
Female
HLA Antigens / blood*
HLA-A Antigens / blood
HLA-B Antigens / blood
HLA-C Antigens / blood
Histocompatibility Antigens Class I / blood
Humans
Male
Middle Aged
Rhinitis, Allergic, Seasonal / immunology,  therapy*
Chemical
Reg. No./Substance:
0/Allergens; 0/HLA Antigens; 0/HLA-A Antigens; 0/HLA-B Antigens; 0/HLA-C Antigens; 0/HLA-G antigen; 0/Histocompatibility Antigens Class I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Efficacy and mechanism of action of KHBJ-9B, a new herbal medicine, and its major compound triterpen...
Next Document:  Testicular mitochondrial alterations in untreated streptozotocin-induced diabetic rats.